Dr Reddy's asked to re-submit Russian vaccine phase-3 trial application

Health Secy says a vaccine should be available in first quarter of next year if everything goes according to plan

Coronavirus, vaccine, covid
A subgroup of the high level committee on vaccine is looking at the logistics situation with respect to syringes and other related equipment besides the vaccine.
Ruchika Chitravanshi New Delhi
2 min read Last Updated : Oct 06 2020 | 10:55 PM IST
The government has asked Dr Reddy’s Laboratories to submit its application for the clinical trials of Russian coronavirus vaccine Sputnik V again, after incorporating some specific suggestions that have been made to them by the  Drugs Controller General of India, health secretary Rajesh Bhushan said on Tuesday. 

Hyderabad-based Dr Reddy Laboratories had recently sought DCGI's permission to conduct phase three trials of the Russian vaccine in India. 

Bhushan also said that a vaccine should be available in the first quarter of next year if everything goes according to plan. 

He said that the government will undertake training of manpower not just for those who have to administer the vaccine but also report any adverse event. 

A subgroup of the high level committee on vaccine is looking at the logistics situation with respect to syringes and other related equipment besides the vaccine. 

While the world awaits the vaccine, as far as the treatment of covid patients goes, plasma therapy has not shown any benefit in mortality in moderate to severe patients nor has it stopped the progression of the disease, the Indian Council Medical Research (ICMR) study has found. “The study has been reviewed and accepted by the British Medical Journal and it will be published soon,” said Balram Bhargava, director general, ICMR. 

The study was conducted on 464 patients across 39 hospitals involving 250 doctors. Taking cue from the plasma therapy ICMR has completed the animal testing of equine sera - blood plasma obtained for horses that have recovered from Covid. It will soon start clinical studies, Bhargava said. 

Health ministry also said that 48 per cent of Covid-19 deaths were in 25 districts across eight states. Fifteen of these districts were in Maharashtra. 

While the government is in talks with the state government there to control the situation, Bhushan also said that there is no direct correlation between health infrastructure and deaths. 

“Patient has to be taken to the hospital in time...In Delhi too we had noticed earlier that most deaths were happening within 72 hours. We have to provide timely treatment,” Bhushan added. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusDr Reddy's LaboratoriesCoronavirus Vaccineclinical trialsICMRHealth Ministry

Next Story